Please login to the form below

Not currently logged in

Paul Stockdale joins Oxford BioDynamics as CFO

He takes over from Katie Long at the UK biotech

Paul Stockdale has joined Oxford BioDynamics as its new chief financial officer and as an executive director on the UK biotech’s board.

He takes over from Katie Long, who has returned to her role within Tessera Investment Management, having previously established and led Oxford BioDynamics’ finance function.

Stockdale arrives at the company from e-Therapeutics, where he had been financial controller since 2012, and has also previously served at Deloitte as a senior manager.

A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

15th September 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....